Here are three findings:
1. In 2013, the market was valued at $1.8 billion.
2. North America dominates the global spinal biologics market, with the U.S. leading the pack.
3. Key companies in the market include DePuy Synthes, NuVasive and Orthofix International.
More articles on biologics:
Anika Therapeutics resumes distribution of cartilage regeneration treatments
AlloSource earns laser etching patent: 3 notes
4 things to know about Bio2 Technologies
